Singletto
Singletto is a biotechnology company revolutionizing antimicrobial protection for healthcare, military, industry, and consumer applications. Their core technology, Oxafence®, leverages Antimicrobial Photodynamic Inactivation (aPDI) using light-activated dyes to generate singlet oxygen, which inactivates viruses and bacteria on treated surfaces. Founded during the COVID-19 pandemic by Drs. James Chen and Thomas Lendvay, Singletto's mission is to deliver ongoing, science-driven Active Protection™ against current and emerging biological threats. The company collaborates with global health leaders, including the WHO and CDC, and partners with manufacturers to develop and commercialize innovative products that actively destroy pathogens during use. Singletto's work is validated by a robust body of peer-reviewed research and ongoing global collaborations.
Patents
What We Do
FDA-cleared ASTM Level 3 surgical masks incorporating Oxafence Active Protection technology, which inactivates 99.9% of tested viruses (including H1N1 Influenza and OC43 Coronavirus) after five minutes of contact. Developed in partnership with Prestige Ameritech, these masks are available in the U.S. and New Zealand.
Oxafence technology was incorporated into Teledyne FLIR’s Integrated Soldier Protective System (ISPS), a smart fabric suit under development for the U.S. Defense Advanced Research Projects Agency (DARPA) Personalized Protective Biosystems Program, to mitigate biological threats for frontline personnel.
Application Area
FDA Regulated Medical Devices
Key People
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Operating Officer
Board Member, Chief Financial Officer, Strategic Advisor
Clinical Solutions
News & Updates
Singletto's Oxafence technology received FDA clearance for use in ProGear ASTM L3 Surgical Masks, now available in the U.S. and New Zealand.
The WHO-led DeMaND study, co-authored by Singletto's leadership, was published in Infection Control & Hospital Epidemiology, validating the efficacy of methylene blue and light for PPE decontamination.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer, was recognized as a Top Doctor by Seattle Magazine.
GeekWire highlighted Singletto as a lead story, focusing on the FDA approval of its Oxafence Active Protection technology for surgical masks and the company's plans for expansion.
Peer-reviewed research, including studies by Singletto co-founders, confirmed the efficacy of Antimicrobial Photodynamic Inactivation (aPDI) against a range of dangerous viruses, supporting the core technology behind Oxafence.
An article by CEO John Bjornson introduces aPDI technology, recaps the WHO DeMaND study, and advocates for better PPE protection.